Effects of vibegron: A Synthesis of Findings from 23 Studies

  1. Home
  2. Effects of vibegron
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of vibegron: A Synthesis of Findings from 23 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of vibegron: A Synthesis of Findings from 23 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major research findings

Vibegron is a new selective β3-adrenoceptor agonist that has shown promising results in treating overactive bladder (OAB) in several studies. 7 , 4 . It is effective in reducing symptoms of OAB, such as frequent urination, urgency, and urge incontinence. 7 , 15 , 21 , 17 . Furthermore, Vibegron has shown to improve quality of life and bladder control ability. 7 , 21 . Research also suggests that Vibegron may be beneficial in treating antimuscarinic-resistant neurogenic bladder dysfunction, specifically in patients with spina bifida. 5 . These findings indicate that Vibegron could be a valuable option for managing OAB and neurogenic bladder dysfunction.

Benefits and risks

Benefits summary

Vibegron has the potential to alleviate the symptoms of OAB and improve quality of life. 7 , 4 . It may also offer relief for patients with antimuscarinic-resistant neurogenic bladder dysfunction. 5 .

Risks summary

Generally, Vibegron is well-tolerated and considered safe. 7 , 15 . However, some patients may experience side effects such as dry mouth, constipation, and gastrointestinal issues. 7 , 15 , 17 . It is important to be aware that Vibegron can also lead to urinary retention. 20 .

Comparison between studies

Commonalities between studies

Multiple studies consistently demonstrate the efficacy of Vibegron in significantly improving OAB symptoms compared to placebo. 7 , 15 , 21 , 17 .

Differences between studies

Some research suggests that Vibegron might be more effective than Mirabegron in reducing voided volume. 17 . Additionally, Vibegron has shown potential for improving antimuscarinic-resistant neurogenic bladder dysfunction, specifically in patients with spina bifida. 5 .

Consistency and contradictions in results

Numerous studies support the effectiveness of Vibegron in treating OAB. 7 , 15 , 21 , 17 . However, some research suggests that Vibegron may be more effective than Mirabegron. 17 . Combining these studies to definitively conclude whether Vibegron surpasses Mirabegron is challenging.

Considerations for real-life application

Vibegron holds the potential to alleviate the symptoms of OAB. 7 , 15 . Nonetheless, it is essential to acknowledge the potential side effects of this medication, including urinary retention and gastrointestinal issues. 7 , 15 , 17 , 20 . Consulting with your doctor to discuss these risks is vital before starting Vibegron. Research also suggests that Vibegron might be helpful for antimuscarinic-resistant neurogenic bladder dysfunction. 5 . However, more research is needed to solidify this finding.

Limitations of current research

The body of research on Vibegron is still relatively limited. 7 , 15 , 21 , 17 . Further research is necessary to understand the long-term effects of Vibegron and its efficacy in specific patient populations.

Future research directions

Additional studies are needed to investigate the long-term safety and efficacy of Vibegron. 7 , 15 , 21 , 17 . Moreover, further research is required to understand the effects of Vibegron on antimuscarinic-resistant neurogenic bladder dysfunction. 5 .

Conclusion

Vibegron shows potential as a new drug for treating OAB. 7 , 15 , 21 , 17 . It is generally safe and well-tolerated. 7 , 15 . However, some patients may experience side effects such as dry mouth, constipation, and gastrointestinal issues. 7 , 15 , 17 . Additionally, Vibegron can lead to urinary retention. 20 . It is essential to discuss the potential risks with your doctor before starting Vibegron.

Literature analysis of 23 papers
Positive Content
21
Neutral Content
1
Negative Content
1
Article Type
5
2
3
4
23
1.

Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladder.

Author: DmochowskiRoger R, RovnerEric S, KennellyMichael J, NewmanDiane K, AbedinzadehLaleh, SnyderDaniel, ThomasElizabeth, Haag-MolkentellerCornelia, RosenbergMatt T

OAB treatment
Tolerability
Vibegron efficacy

Vibegron is a new drug approved for the treatment of overactive bladder (OAB). This article describes the COMPOSUR study, a real-world study evaluating the effectiveness, tolerability, safety, and duration of treatment with vibegron.

Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

2.

Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.

Author: EdmondsonScott D, ZhuCheng, KarNam Fung, Di SalvoJerry, NagabukuroHiroshi, Sacre-SalemBeatrice, DingleyKaren, BergerRichard, GobleStephen D, MorrielloGregori, HarperBart, MoyesChristopher R, ShenDong-Ming, WangLiping, BallRichard, FitzmauriceAileen, FrenklTara, GichuruLoise N, HaSookhee, HurleyAmanda L, JochnowitzNina, LevorseDorothy, MistryShruty, MillerRandy R, OrmesJames, SalituroGino M, SanfizAnthony, StevensonAndra S, VillaKatherine, ZamlynnyBeata, GreenStuart, StruthersMary, WeberAnn E

Improved druglike properties
OAB treatment
Superior preclinical profile
Vibegron efficacy

This article describes the discovery of vibegron, a new drug for treating overactive bladder. Vibegron is a potent and selective agonist of a specific receptor that is involved in bladder function.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

3.

Comparison of Mirabegron and Vibegron in Women With Treatment-Naive Overactive Bladder: A Randomized Controlled Study.

Author: KinjoManami, MasudaKazuki, NakamuraYu, MiyakawaJimpei, TamboMitsuhiro, FukuharaHiroshi

Improved OAB symptoms

Both mirabegron and vibegron, at a dose of 50 mg daily, effectively improved overactive bladder (OAB) symptoms in postmenopausal women. Both drugs significantly reduced OAB symptom scores, quality of life index, and the number of micturition, urgency, and incontinence episodes. Both medications were well tolerated, with similar rates of discontinuation due to adverse effects.

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

7.

Vibegron, a Novel Potent and Selective &#946;<sub>3</sub>-Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-blind, Placebo-controlled Phase 3 Study.

Author: YoshidaMasaki, TakedaMasayuki, GotohMomokazu, NagaiShinji, KuroseTakafumi

Vibegron for OAB

Vibegron demonstrated efficacy and safety in treating overactive bladder (OAB) in Japanese patients, with improvements in symptoms and quality of life.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

8.

Pharmacophore-guided Virtual Screening to Identify New &#946;<sub>3</sub> -adrenergic Receptor Agonists.

Author: UjiantariNavista Sri Octa, HamSeungmin, NagiriChisae, ShihoyaWataru, NurekiOsamu, HutchinsonDana Sabine, SchusterDaniela

Bladder relaxation
Increased blood pressure

This study aimed to identify new β3-AR agonists for drug development. A pharmacophore model was developed and used for virtual screening, followed by in vitro validation. Out of 35 tested compounds, 4 were active in CHO-K1 cells expressing the human β3-AR, and 8 were active in cells expressing the mouse β3-AR.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

11.

An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive Bladder.

Author: FrankelJeffrey, StaskinDavid, VaranoSusann, KennellyMichael J, JankowichRachael A, Haag-MolkentellerCornelia

Improved quality of life
Overactive bladder treatment

Vibegron, a beta-3 adrenergic receptor agonist, has been shown to be effective and well-tolerated for the treatment of overactive bladder in two large clinical trials.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

13.

Efficient biosynthesis of Vibegron intermediate using a novel carbonyl reductase based on molecular modification of hydrogen bonding network regulation.

Author: ZhangXiao-Jian, YangFei, ChenKai-Li, FangWei-Mei, LiuZhi-Qiang, ZhengYu-Guo

Improved efficiency
Vibegron synthesis

Vibegron is a drug that is used to treat overactive bladder. A study investigated the use of a novel carbonyl reductase from Exiguobacterium sp. s126 (EaSDR6) in the synthesis of a key chiral intermediate for the synthesis of Vibegron.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

14.

Urodynamic effectiveness of a beta-3 adrenoreceptor agonist (vibegron) for a pediatric patient with anticholinergic-resistant neurogenic detrusor overactivity: a case report.

Author: KatoTaiki, MizunoKentaro, NishioHidenori, YasuiTakahiro, HayashiYutaro

NDO treatment

This case report describes the use of vibegron, a selective beta-3 adrenoreceptor agonist, to treat anticholinergic-resistant neurogenic detrusor overactivity (NDO) in a young girl with tethered cord syndrome following myelomeningocele repair.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

15.

The efficacy and safety of Vibegron in treating overactive bladder: A systematic review and pooled analysis of randomized controlled trials.

Author: ShiHongbin, ChenHongyan, ZhangYong, CuiYuanshan

Overactive bladder treatment
Dry mouth

Vibegron, a β3-adrenergic receptor agonist, significantly improved overactive bladder symptoms in patients compared to placebo. The treatment was well-tolerated with a favorable safety profile, with dry mouth being the most common side effect.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

17.

Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta-analysis.

Author: HeWenjuan, ZhangYuqian, HuangGuangliang, TianYunfei, SunQian, LiuXiuju

Mirabegron efficacy
Vibegron efficacy
Mirabegron side effects

Both mirabegron and vibegron were more effective than placebo in reducing overactive bladder (OAB) symptoms. Vibegron was found to be more effective than mirabegron in reducing mean voided volume per micturition. Both drugs were well tolerated, with similar safety profiles to placebo, except for mirabegron which had a higher risk of nasopharyngitis and cardiovascular adverse events.

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

18.

Efficacy of novel &#946;<sub>3</sub> -adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study.

Author: YoshidaMasaki, TakedaMasayuki, GotohMomokazu, YokoyamaOsamu, KakizakiHidehiro, TakahashiSatoru, MasumoriNaoya, NagaiShinji, HashimotoKeita, MinemuraKazuyoshi

Improved nocturia
Reduced voiding frequency

Vibegron significantly reduced the frequency of nocturnal voiding in patients with overactive bladder compared to placebo. The study also found that vibegron treatment was associated with a greater mean volume of nocturnal voids and a greater volume of the first nocturnal voiding compared to placebo.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

19.

Mirabegron versus vibegron in previously untreated female patients with overactive bladder: A randomized, single-clinic, open-label trial.

Author: SatoHirotaka, OtsukaShota, TsukadaSachiyuki

Effective OAB treatment
Vibegron safety concerns

Mirabegron and vibegron, both at a dosage of 50 mg once daily, were effective in treating female OAB patients. Although no statistically significant difference was observed in efficacy between the two drugs, vibegron was associated with a higher incidence of treatment-related adverse events.

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

21.

Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis.

Author: MostafaeiHadi, Salehi-PourmehrHanieh, JilchSandra, CarlinGreta Lisa, MoriKeiichiro, QuhalFahad, PradereBenjamin, GrossmannNico C, LaukhtinaEkaterina, SchuettfortVictor M, AydhAbdulmajeed, Sari MotlaghReza, KönigFrederik, RoehrbornClaus G, KatayamaSatoshi, RajwaPawel, HajebrahimiSakineh, ShariatShahrokh F

Improved bladder function
Reduced urinary symptoms
Gastrointestinal side effects

A network meta-analysis of 54 randomized controlled trials involving patients with idiopathic overactive bladder (IOAB) compared the efficacy of oral antimuscarinics and β-adrenoceptor agonists, considering adverse events. The most efficacious agents for reducing various overactive bladder symptoms varied depending on the specific symptom, and gastrointestinal problems were the most common adverse events. The findings highlight the importance of shared decision-making with patients to select the most appropriate treatment based on individual symptoms and tolerability.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

22.

Patient and Clinician Challenges with Anticholinergic Step Therapy in the Treatment of Overactive Bladder: A Narrative Review.

Author: DmochowskiRoger R, NewmanDiane K, RovnerEric S, ZilliouxJacqueline, MalikRena D, AckermanA Lenore

Cognitive decline

Anticholinergics have been a mainstay treatment for overactive bladder (OAB), but their use is increasingly limited due to concerns about tolerability and cognitive decline. While newer medications, such as β3-adrenergic receptor agonists, offer better tolerability, patient access to these medications can be restricted by insurance policies that require step therapy, leading to potential treatment delays and harm.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

23.

Efficacy of vibegron in patients with overactive bladder: Multicenter prospective study of real-world clinical practice in Japan, SCCOP study 19-01.

Author: TachikawaKimihito, KyodaYuki, FukutaFumimasa, KobayashiKo, MasumoriNaoya

Effective
Well tolerated

This real-world clinical study evaluated the efficacy and safety of vibegron in patients with overactive bladder in Japan. The results showed that vibegron was effective and well-tolerated, including in patients switching therapy from antimuscarinics and mirabegron. No grade 3 or higher adverse events were observed.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.